Search

1 to 10 of 224
Sort by

Library Entry
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

Although several therapeutic options for patients with renal cell carcinoma (RCC) have been approved over recent years, including immune checkpoint inhibitors, considerable need remains for molecular biomarkers to assess disease prognosis. The higher pharmacokinetic (PK) clearance of checkpoint...


Library Entry
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study was to investigate the incidence rates of irAEs and their correlations with objective...


Library Entry
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. The authors hypothesized that BoM may influence sensitivity to immunotherapy. They conclude that BoM impairs...



Library Entry
Immunotherapy for the Treatment of Head & Neck Cancers - A Patient Resource Guide

Learning you have head and neck cancer can fell overwhelming. Give yourself time to digest the news, and then focus on learning as much as you can about your exact diagnosis. Knowing ket information will better prepare you to make well-informed decisions with your doctor. This guide, published...

2019 Immunotherapy H&N.pdf


Library Entry
Dual checkpoint inhibitor-associated eosinophilic enteritis

Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events. The authors report a case of dual checkpoint inhibitor-associated hypereosinophilia and...


Library Entry
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with the...


Library Entry
Pericardial effusion under nivolumab: case-reports and review of the literature

Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, initially...


Library Entry
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma

Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs are rare compared to the more typical skin, gastrointestinal, and endocrine toxicities,...